SIRT6-focused biotech cements longevity focus with heavyweight appointment

Nir Barzilai joins SIRTLab Board as Chief Medical Advisor.

Longevity research is a complex and multifactorial field, areas of which are still poorly understood, and the lack of financial incentives and the high costs associated with research mean some companies swerve the longevity branding, preferring seemingly-more attractive areas of focus for straplines and slide decks.

My take on this: However, interest in longevity is gaining serious ground – after all, we all have a vested interest in progress in the space. There are economic upsides to improving lifespan and healthspan as well, with a recent paper calculating that a slowdown in aging that increases life expectancy by one year is worth $38 trillion, and for ten years $367 trillion.

SIRTLab Corporation, is one such company that has nailed its longevity colors to the mast; a US Company with research laboratories in the Weizmann Science Park, Israel, SIRTLab has patented a suite of advanced technologies to raise the specific and direct activity of SIRT6 protein to treat various age-related diseases for multiple large markets and existing needs. The company styles itself as “focused on longevity”, and includes liver disease, frailty, metabolic syndrome, neurodegeneration and inflammatory conditions among its targets.

The company was founded by Boaz Misholi and Professor Haim Cohen, a world leader in research of SIRT6, who has seen over $40 million invested in his research.

Get to know more about SIRTLab and its new Chief Medical Advisor, Dr Nir Barzilai, HERE.

Thank you for reading! If you enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!